BR112017018620A2 - método de administração de tradipitanto, e, tradipitanto. - Google Patents

método de administração de tradipitanto, e, tradipitanto.

Info

Publication number
BR112017018620A2
BR112017018620A2 BR112017018620-9A BR112017018620A BR112017018620A2 BR 112017018620 A2 BR112017018620 A2 BR 112017018620A2 BR 112017018620 A BR112017018620 A BR 112017018620A BR 112017018620 A2 BR112017018620 A2 BR 112017018620A2
Authority
BR
Brazil
Prior art keywords
tradipitanto
administration
tradipitant
treatment method
application relates
Prior art date
Application number
BR112017018620-9A
Other languages
English (en)
Portuguese (pt)
Inventor
H. Polymeropoulos Mihael
William Licamele Louis
Original Assignee
Vanda Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc. filed Critical Vanda Pharmaceuticals Inc.
Publication of BR112017018620A2 publication Critical patent/BR112017018620A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112017018620-9A 2015-03-04 2016-03-04 método de administração de tradipitanto, e, tradipitanto. BR112017018620A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562128472P 2015-03-04 2015-03-04
US62/128472 2015-03-04
US201562232644P 2015-09-25 2015-09-25
US62/232644 2015-09-25
PCT/US2016/021015 WO2016141341A1 (en) 2015-03-04 2016-03-04 Method of treatment with tradipitant

Publications (1)

Publication Number Publication Date
BR112017018620A2 true BR112017018620A2 (pt) 2018-04-17

Family

ID=55629110

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018620-9A BR112017018620A2 (pt) 2015-03-04 2016-03-04 método de administração de tradipitanto, e, tradipitanto.

Country Status (20)

Country Link
US (6) US10463655B2 (cg-RX-API-DMAC10.html)
EP (2) EP3265087B1 (cg-RX-API-DMAC10.html)
JP (4) JP6891385B2 (cg-RX-API-DMAC10.html)
KR (3) KR102860817B1 (cg-RX-API-DMAC10.html)
CN (2) CN113262221A (cg-RX-API-DMAC10.html)
AU (4) AU2016226006B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017018620A2 (cg-RX-API-DMAC10.html)
CA (2) CA3213864C (cg-RX-API-DMAC10.html)
CL (1) CL2017002238A1 (cg-RX-API-DMAC10.html)
DK (2) DK3265087T3 (cg-RX-API-DMAC10.html)
ES (1) ES2824552T3 (cg-RX-API-DMAC10.html)
FI (1) FI3730140T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20201627T1 (cg-RX-API-DMAC10.html)
HU (1) HUE050944T2 (cg-RX-API-DMAC10.html)
IL (1) IL254142B (cg-RX-API-DMAC10.html)
MX (2) MX385788B (cg-RX-API-DMAC10.html)
PT (2) PT3265087T (cg-RX-API-DMAC10.html)
RU (1) RU2770050C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016141341A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201706059B (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2770050C2 (ru) * 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
DK3710000T3 (da) * 2017-11-17 2025-06-16 Vanda Pharmaceuticals Inc Tradipitant til anvendelse til behandling af gastroparese
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
IL281569B2 (en) 2018-09-28 2025-04-01 Vanda Pharmaceuticals Inc Use of tradipient in motion sickness
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
KR20220145844A (ko) 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305718D0 (en) 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
TW263498B (cg-RX-API-DMAC10.html) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
GB9513972D0 (en) 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
AU2003230829B8 (en) * 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
SI1501808T1 (sl) * 2002-04-26 2008-10-31 Lilly Co Eli Antagonisti tahikininskega receptorja
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005042515A1 (en) * 2003-10-24 2005-05-12 Eli Lilly And Company Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Th1型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
WO2007096782A2 (en) 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compositions for disorders associated wtth metachromatic cell activation
EP2121610B1 (en) 2006-12-20 2014-04-02 Eli Lilly & Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
EP2464230B1 (en) 2009-08-14 2016-10-05 OPKO Health, Inc. Intravenous formulations of rolapitant
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
PE20121483A1 (es) 2009-11-18 2012-12-02 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados
EP2931253A1 (en) 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
CA2915474A1 (en) * 2013-06-24 2014-12-31 Tigercat Pharma, Inc. Use of nk-1 receptor antagonist serlopitant in pruritus
US8906951B1 (en) * 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
RU2770050C2 (ru) * 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
WO2016195723A1 (en) 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017093857A1 (en) 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions
EA201891472A1 (ru) 2015-12-22 2018-12-28 Такеда Фармасьютикал Компани Лимитед Тройные модуляторы эндосомальных рецепторов, сопряженных с g-белком
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
DK3710000T3 (da) * 2017-11-17 2025-06-16 Vanda Pharmaceuticals Inc Tradipitant til anvendelse til behandling af gastroparese
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
IL281569B2 (en) 2018-09-28 2025-04-01 Vanda Pharmaceuticals Inc Use of tradipient in motion sickness
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Also Published As

Publication number Publication date
EP3730140A1 (en) 2020-10-28
MX2021010460A (es) 2021-09-21
AU2021202956A1 (en) 2021-06-03
HK1248552A1 (zh) 2018-10-19
CL2017002238A1 (es) 2018-04-20
FI3730140T3 (fi) 2026-07-14
EP3730140B1 (en) 2026-05-06
IL254142A0 (en) 2017-10-31
US10463655B2 (en) 2019-11-05
RU2017134443A (ru) 2019-04-04
CN107427502B (zh) 2021-06-04
MX2017011279A (es) 2018-01-25
US11324735B2 (en) 2022-05-10
AU2021202956B2 (en) 2023-06-29
WO2016141341A1 (en) 2016-09-09
CA3213864C (en) 2026-02-03
CA3213864A1 (en) 2016-09-09
AU2025210905A1 (en) 2025-08-21
CN113262221A (zh) 2021-08-17
US20200360358A1 (en) 2020-11-19
HRP20201627T1 (hr) 2021-02-19
PT3265087T (pt) 2020-10-15
RU2017134443A3 (cg-RX-API-DMAC10.html) 2019-09-05
MX385788B (es) 2025-03-18
US10772880B2 (en) 2020-09-15
JP2023052486A (ja) 2023-04-11
US20190290626A1 (en) 2019-09-26
KR20230173743A (ko) 2023-12-27
JP2018507243A (ja) 2018-03-15
NZ735121A (en) 2024-07-26
DK3730140T3 (da) 2026-07-27
AU2023233141B2 (en) 2025-05-22
US20250205213A1 (en) 2025-06-26
KR20170122777A (ko) 2017-11-06
CA2978736A1 (en) 2016-09-09
ZA201706059B (en) 2023-08-30
KR20250136946A (ko) 2025-09-16
KR102860817B1 (ko) 2025-09-16
DK3265087T3 (da) 2020-10-19
HUE050944T2 (hu) 2021-01-28
US20180110761A1 (en) 2018-04-26
ES2824552T3 (es) 2021-05-12
RU2770050C2 (ru) 2022-04-14
US20220226295A1 (en) 2022-07-21
JP2024074963A (ja) 2024-05-31
PT3730140T (pt) 2026-07-16
AU2016226006A1 (en) 2017-09-21
US12318375B2 (en) 2025-06-03
JP2021073258A (ja) 2021-05-13
CA2978736C (en) 2023-11-07
EP3265087B1 (en) 2020-07-22
AU2023233141A1 (en) 2023-10-12
AU2016226006B2 (en) 2021-03-04
US20190290625A1 (en) 2019-09-26
JP6891385B2 (ja) 2021-06-18
CN107427502A (zh) 2017-12-01
EP3265087A1 (en) 2018-01-10
IL254142B (en) 2022-05-01

Similar Documents

Publication Publication Date Title
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
MX2021010460A (es) Metodo de tratamiento con tradipitant.
NZ730809A (en) Methods for treating filoviridae virus infections
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201890204A1 (ru) Антибактериальные соединения
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
MX2019005833A (es) Administracion transdermica de agentes grandes.
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
ZA201703467B (en) Methods of treating ocular conditions
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
IN2014CH00840A (cg-RX-API-DMAC10.html)
EA201792527A1 (ru) Лечение зуда
MX2023009431A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio.
CL2016000396A1 (es) Tratamiento contra el mieloma múltiple
PL3128840T3 (pl) Produkt użyźniający i biostymulujący zawierający fruktooligosacharydy, sposób jego podawania i jego zastosowania
EA201792578A1 (ru) Многослойная сборка
PH12016502111A1 (en) Drug for treatment of tinnitus patients
BR112018008181A2 (pt) baclofen intravenoso e métodos de tratamento
GEAP201814327A (en) Treatment regimen tiacumicin compound
MX2022010854A (es) Peptidos toxicos activados artificialmente.
GEAU201814383U (en) Method for helmintox drug preparation
UA104671U (uk) Застосування яктону як нейропротектора

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]